TY - JOUR T1 - IGI-LuNER: single-well multiplexed RT-qPCR test for SARS-CoV-2 JF - medRxiv DO - 10.1101/2020.12.10.20247338 SP - 2020.12.10.20247338 AU - Elizabeth C. Stahl AU - Connor A. Tsuchida AU - Jennifer R. Hamilton AU - Enrique Lin-Shiao AU - Shana L. McDevitt AU - Erica A. Moehle AU - Lea B. Witkowsky AU - C. Kimberly Tsui AU - Kathleen Pestal AU - Holly K. Gildea AU - Matthew McElroy AU - Amanda Keller AU - Iman Sylvain AU - Clara Williams AU - Ariana Hirsh AU - Alison Ciling AU - Alexander J. Ehrenberg AU - IGI SARS-CoV-2 consortium AU - Fyodor D. Urnov AU - Bradley R. Ringeisen AU - Petros Giannikopoulos AU - Jennifer A. Doudna Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/12/11/2020.12.10.20247338.abstract N2 - Commonly used RT-qPCR-based SARS-CoV-2 diagnostics require 2-3 separate reactions or rely on detection of a single viral target, adding time and cost or risk of false-negative results. Currently, no test combines detection of widely used SARS-CoV-2 E- and N-gene targets and a sample control in a single, multiplexed reaction. We developed the IGI-LuNER RT-qPCR assay using the Luna Probe Universal One-Step RT-qPCR master mix with publicly available primers and probes to detect SARS-CoV-2 N gene, E gene, and human RNase P (NER). This combined, cost-effective test can be performed in 384-well plates with detection sensitivity suitable for clinical reporting, and will aid in future sample pooling efforts, thus improving throughput of SARS-CoV-2 detection.Competing Interest StatementThe Regents of the University of California have patents issued and pending for CRISPR technologies on which J.A.D. is an inventor. J.A.D. is a cofounder of Caribou Biosciences, Editas Medicine, Scribe Therapeutics, Intellia Therapeutics and Mammoth Biosciences. J.A.D. is a scientific advisory board member of Caribou Biosciences, Intellia Therapeutics, eFFECTOR Therapeutics, Scribe Therapeutics, Mammoth Biosciences, Synthego, Algen Biotechnologies, Felix Biosciences and Inari. J.A.D. is a Director at Johnson & Johnson and has research projects sponsored by Biogen, Pfizer, AppleTree Partners and Roche. F.D.U. is a co-founder of Tune Therapeutics. P.G. is a cofounder and Director at NewCo Health. P.G. is the CLIA Laboratory Director for Coral Genomics and 3DMed. The other authors declare no competing interests.Funding StatementThis study was funded by gifts from the Packard Foundation and the Curci Foundation to the Innovative Genomics Institute at UC Berkeley. J.R.H. is a Fellow of The Jane Coffin Childs Memorial Fund for Medical Research. K.P. is a Cancer Research Institute Irvington Fellow supported by the Cancer Research Institute. H.K.G is supported by NSF Grant # DGE175814 and NIA 1F99AG068343-01.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Descriptive statistics for patient samples used in this manuscript come from de-identified datasets in accordance with human subjects protections as approved by the UC Berkeley Committee for Protection of Human Subjects (CPHS). While Institutional Review Board (IRB) approval is required for any research using human subjects clinical laboratory activities exclusively supporting CLIA-certified clinical operations do not. These activities are governed by CMS and HIPAA legislation. In order to publish our data in this manuscript as results of developing a testing workstream, we sought IRB approval through UC Berkeley CPHS. The UC Berkeley Committee for Protection of Human Subjects determined that all the analyses presented in this manuscript do not qualify as human subjects research as the data sets were de-identified to those analyzing them for these results (IRB submission # 2020-04-13177).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data included in this article and the supplementary files are available upon request to the corresponding authors. ER -